Previous 10 | Next 10 |
- 50% confirmed overall response rate, including one (13%) confirmed complete response in eight urothelial cancer patients dosed at 5.0mg/m 2 weekly - Median duration of response not yet reached in the 2.5mg/m 2 and 5.0mg/m 2 weekly cohorts; four of five responders in th...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Bicycle Therapeutics (NASDAQ:BCYC) is trading sharply higher on Friday after the clinical-stage biotech announced promising interim Phase I results for its cancer candidate BT8009 in a group of patients with solid tumors. The data were shared at the ongoing 2022 American Association for Cance...
- Company to Host Conference Call on Monday, April 11, 2022 at 8:30 a.m. ET Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, ...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced updated preclinical results providing further evidence for Bicycles ...
Bicycle Therapeutics plc (NASDAQ:BCYC) traded at a new 52-week high today of $62.19. This new high was reached on above average trading volume as 3.5 million shares traded hands, while the average 30-day volume is approximately 261,000 shares. Bicycle Therapeutics plc share prices have m...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that management will participate in a fireside chat at the 21 st Ann...
Shares of Bicycle Therapeutics have risen by 68% over the past 12 months and 252% over the past 3 years. I provide a recap of the bullish thesis and my prior notes on this differentiated platform technology play. Bicycle Toxin Conjugates (BTCs) appear to have several advantages ov...
- Four Additional Abstracts Selected as Poster Presentations at the Meeting - Company to Host Conference Call on Monday, April 11, 2022 at 8:30 a.m. ET Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of thera...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that management will participate in a fireside chat at the Oppenheimer 3...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
Bicycle Therapeutics plc Website:
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced the acceptance of four abstracts for poster presentation at the European So...
2024-06-10 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates ® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate,...